IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Argentina

  • ID: 1408471
  • Report
  • Region: Argentina
  • 41 Pages
  • IMS Health
1 of 3

The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets. This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.

Note: Product cover images may vary from those shown
2 of 3

1. Healthcare System

  • Facts & Figures
  • Market Indicators
  • Provision & Funding
  • New Universal Health Insurance System
  • Existing Healthcare System
  • Policy, Regulation, and Funding

2. Pricing

  • Prescription Drugs
  • Generic Drugs
  • Hospital Drugs
  • Public Hospitals
  • Direct Negotiations
  • OTC Drugs

3. Reimbursement

  • Admission to Reimbursement
  • PMOE Formulary
  • Individual Formularies
  • Non-PMOE Drugs
  • High-cost Drugs
  • Public Sector Formularies
  • Expanded Access Programmes
  • Reimbursement Categories
  • PMOE Formulary Drugs
  • Non-PMOE Formulary Drugs
  • Redistribution Fund for High-cost Drugs
  • Public Sector Patients
  • Reimbursement Prices
  • Manufacturer Subsidies
  • Reference Prices
  • Hospital Reimbursement
  • Formularies
  • Funding
  • Changes in Reimbursement Status
  • PMOE Formulary
  • Individual Formularies
  • Changes in Reimbursement Prices
  • Price Controls
  • Price Caps
  • Ad Hoc Price Increases
  • PAMI
  • Discounts

4. Pharmacoeconomics

  • Pharmacoeconomic Requirements
  • PMOE
  • National HTA Agency
  • PAMI
  • SUR

5. Price Build Up

  • Wholesalers
  • Margins
  • Background
  • Retail Pharmacies
  • Margins
  • Background
  • OTC Sales
  • E-Pharmacy
  • Dispensing Doctors
  • Sales Tax

6. Cost Containment

  • Industry Paybacks
  • Promotional Costs
  • Patient Co-payments
  • Insured Patients
  • Uninsured Patients
  • Prescribing Controls
  • Generics
  • Bioequivalence
  • Intellectual Property
  • INN Prescribing and Generic Substitution
  • Rx-to-OTC Switches
  • OTC Market
  • Parallel Trade
  • Counterfeit Trade

7. Future Developments

  • Outlook
  • Reimbursement System Overhaul
  • Health Technology Assessment
  • Price Controls
  • PAMI-Industry Agreement
  • Universal Health Insurance System
  • New Supply Network of Drugs

8. Names & Addresses

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll